ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Observational Data Show Transfusion Patterns In Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis Stimulating Agents
Two new analyses of observational
data presented at Community Oncology Conference reported a
significantly lower proportion of patients receiving transfusions when
erythropoiesis- stimulating agents (ESAs) treatment was initiated at
hemoglobin (Hb) levels between 10 to 11 grams per deciliter (g/dL) of blood
compared with patients having Hb levels less than 10 g/dL prior to ESA
treatment. In addition, wide variability in hemoglobin levels prior to
transfusion was reported.
These analyses were conducted using data from the ongoing prospective,
observational Dosing and Outcomes Study of Erythropoiesis-Stimulating
Therapies (DOSE) Registry, sponsored by Centocor Ortho Biotech Services,
L.L.C.
"Observational data reflect real-world clinical practice and therefore
these findings are important in helping to understand transfusion
patterns," said Kay Larholt, Sc.D., Vice President, Biometrics at Abt
Associates, a biopharmaceutical research and consulting firm, and lead
author of both analyses presented today. "The analyses indicate that the
presence of a lower hemoglobin when ESA therapy was initiated was
associated with a higher need for transfusion, and suggest initiation at a
hemoglobin between 10 to 11 g/dL may reduce the need for transfusion."
Methodology and Results
For both analyses, real-world data on ESA-treated patients in 48 U.S.
oncology clinics were analyzed from the DOSE Registry. Data were collected
from participating hospital- and community-based outpatient practices
between December 2003 and July 2007.
In the first analysis of 969 patients, transfusion data were analyzed
from adult chemotherapy-treated oncology patients that received at least
two ESA doses. Results of the analysis were as follows:
-- A significantly greater proportion of chemotherapy-treated patients
received transfusions when ESA treatment was initiated at Hb levels
below 10 g/dL compared with patients having Hb levels of 10 to 11 g/dL
prior to ESA administration: 31% vs. 14%, respectively, p
Observaþional de date Arata modele de transfuzie în anemie indusã de chimioterapie, pacienþii care au primit agenþi de stimulare a eritropoezei - Observational Data Show Transfusion Patterns In Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis Stimulating Agents - articole medicale engleza - startsanatate